PRECIPIO INC (PRPO) Stock Price, Quote, News and Overview
NASDAQ:PRPO - Nasdaq - US74019L6020 - Common Stock - Currency: USD
PRPO Quote, Performance and Key Statistics
NASDAQ:PRPO (2/21/2025, 8:00:01 PM)
10.14
+0.5 (+5.19%)
The current stock price of PRPO is 10.14 USD. In the past month the price increased by 56.91%. In the past year, price increased by 63.29%.
PRPO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CI | THE CIGNA GROUP | 10.97 | 82.08B | ||
| CVS | CVS HEALTH CORP | 11.71 | 79.88B | ||
| LH | LABCORP HOLDINGS INC | 17.15 | 20.84B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.1 | 19.12B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.74 | 13.55B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 148.77 | 12.18B | ||
| DVA | DAVITA INC | 14.99 | 11.68B | ||
| HIMS | HIMS & HERS HEALTH INC | 112 | 10.77B | ||
| CHE | CHEMED CORP | 23.84 | 8.18B | ||
| CRVL | CORVEL CORP | 25.97 | 5.57B | ||
| OPCH | OPTION CARE HEALTH INC | 26.89 | 5.45B | ||
| GH | GUARDANT HEALTH INC | N/A | 5.30B |
Related stock screener links
About PRPO
Company Profile
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. The company is headquartered in New Haven, Connecticut and currently employs 51 full-time employees. The company went IPO on 2000-07-18. The company develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Company Info
PRECIPIO INC
4 Science Park
New Haven CONNECTICUT 06511 US
CEO: Ilan Danieli
Employees: 54
Company Website: http://www.precipiodx.com/
Investor Relations: http://www.transgenomic.com/ir/investor-information/
Phone: 12037877888
PRECIPIO INC / PRPO FAQ
What is the stock price of PRECIPIO INC today?
The current stock price of PRPO is 10.14 USD. The price increased by 5.19% in the last trading session.
What is the ticker symbol for PRECIPIO INC stock?
The exchange symbol of PRECIPIO INC is PRPO and it is listed on the Nasdaq exchange.
On which exchange is PRPO stock listed?
PRPO stock is listed on the Nasdaq exchange.
What is PRECIPIO INC worth?
PRECIPIO INC (PRPO) has a market capitalization of 15.01M USD. This makes PRPO a Nano Cap stock.
How many employees does PRECIPIO INC have?
PRECIPIO INC (PRPO) currently has 54 employees.
What are the support and resistance levels for PRECIPIO INC (PRPO) stock?
PRECIPIO INC (PRPO) has a support level at 7.23. Check the full technical report for a detailed analysis of PRPO support and resistance levels.
Is PRECIPIO INC (PRPO) expected to grow?
The Revenue of PRECIPIO INC (PRPO) is expected to grow by 65.19% in the next year. Check the estimates tab for more information on the PRPO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PRECIPIO INC (PRPO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PRPO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PRPO, evaluating the profitability, health, valuation and growth aspects
- PRECIPIO INC (PRPO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PRECIPIO INC (PRPO) Sales and EPS estimates to see what analysts future expectations are.
- PRECIPIO INC (PRPO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PRECIPIO INC (PRPO) Insider and Institutional Ownership to learn about the owners and their transactions.
- PRECIPIO INC (PRPO) Stock Chart to make your own analysis
- PRECIPIO INC (PRPO) Latest news and press-releases to stay up to date.
Does PRECIPIO INC (PRPO) stock pay dividends?
PRPO does not pay a dividend.
When does PRECIPIO INC (PRPO) report earnings?
PRECIPIO INC (PRPO) will report earnings on 2025-03-31, after the market close.
What is the Price/Earnings (PE) ratio of PRECIPIO INC (PRPO)?
PRECIPIO INC (PRPO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.06).
What is the Short Interest ratio of PRECIPIO INC (PRPO) stock?
The outstanding short interest for PRECIPIO INC (PRPO) is 1.79% of its float. Check the ownership tab for more information on the PRPO short interest.
PRPO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PRPO. When comparing the yearly performance of all stocks, PRPO is one of the better performing stocks in the market, outperforming 95.88% of all stocks.
PRPO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PRPO. PRPO may be in some trouble as it scores bad on both profitability and health.
PRPO Financial Highlights
Over the last trailing twelve months PRPO reported a non-GAAP Earnings per Share(EPS) of -2.06. The EPS increased by 72.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.7% | ||
| ROE | -25.12% | ||
| Debt/Equity | 0.02 |
PRPO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PRPO. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 106.24% and a revenue growth 65.19% for PRPO